Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.13% | 17.70% | 17.76% | -394.45% | 84.86% |
| Total Depreciation and Amortization | -1.25% | -21.31% | -14.53% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.29% | -15.22% | 15.72% | -21.59% | 0.82% |
| Change in Net Operating Assets | 18.69% | -462.09% | 0.65% | 109.19% | -453.04% |
| Cash from Operations | 9.39% | -59.86% | 30.78% | 14.61% | 34.12% |
| Capital Expenditure | 100.00% | 94.02% | 26.69% | -191.86% | 92.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.78% | -339.61% | -53.07% | 1,409.38% | 117.67% |
| Cash from Investing | 142.77% | -342.03% | -53.23% | 1,449.96% | 115.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 3,441,066.67% | -97.64% | -- | -100.00% |
| Repurchase of Common Stock | -161.25% | -138.81% | -168.00% | 58.33% | 66.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.41% | 161,154.69% | -162.75% | 270.00% | -190.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.40% | 299.46% | -509.94% | 104.51% | 49.80% |